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Abstract  
Converging evidence indicates that the prefrontal cortex is critically involved in executive 
control and that executive dysfunction is implicated in schizophrenia. Reduced dopamine D2/D3 
receptor binding potential has been reported in schizophrenia, and the correlations with 
neuropsychological test scores have been positive and negative for different tasks. The aim of 
this study was to examine the relation between dopamine D2/D3 receptor levels with frontal and 
temporal neurocognitive performance in schizophrenia. Resting-state 
18
F-fallypride positron 
emission tomography was performed on 20 medication-naïve and 5 previously medicated for 
brief earlier periods patients with schizophrenia and 19 age- and sex-matched normal controls. 
Striatal and extra-striatal dopamine D2/D3 receptor levels were quantified as binding potential 
using fallypride imaging. Magnetic resonance images in standard Talairach position and 
segmented into gray and white matter were co-registered to the fallypride images, and the AFNI 
stereotaxic atlas was applied. Two neuropsychological tasks known to activate frontal and 
temporal lobe function were chosen, specifically the Wisconsin Card Sorting Test (WCST) and 
the California Verbal Learning Test (CVLT). Images of the correlation coefficient between 
fallypride binding and WCST and CVLT performance showed a negative correlation in contrast 
to positive correlations in healthy volunteers. The results of this study demonstrate that lower 
fallypride binding potential in patients with schizophrenia may be associated with better 
performance. Our findings are consistent with previous studies that failed to find cognitive 
improvements with typical dopamine-blocking medications.  
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1. Introduction 
 Neurocognitive impairments are a core feature of schizophrenia, with the largest effect 
sizes (greater than 1.5 z-score differences) reported in both executive function and verbal 
memory (Bilder et al., 2000; Dickinson and Harvey, 2009; Reichenberg et al., 2010; Vyas et al., 
2012). Impairments in executive function are found to predict poor functional outcome, failure  
in treatment interventions and limited rehabilitation (Green et al., 2000). Executive function 
includes multiple cognitive constructs regulated by the coordination of multi-operational neural 
systems and is a linchpin of cognitive ability (Bressler and Menon, 2010). It has been linked in 
functional neuroimaging studies to the fronto-striatal-thalamic network thought to be associated 
with the pervasive cognitive deficits reported in schizophrenia (Andreasen, 1997; Andreasen et 
al., 1997; Buchsbaum et al., 1999; Hazlett et al., 2008; Kessler et al., 1993). This network, with 
its detailed neuroanatomical structure (Alexander et al., 1986) is critical for performing tasks 
such as the Wisconsin Card Sorting Test (WCST) that are known to elicit performance 
impairments in schizophrenia, and its dysfunctional operation demonstrated in unmedicated 
schizophrenia patients confirmed  with functional brain imaging approaches (see review and 
meta-analysis  (Buchsbaum et al., 2005).  Abnormalities in the fronto-striatal-thalamic network 
have also been demonstrated in functional magnetic resonance imaging (fMRI) studies of 
psychosis-prone individuals (Ettinger et al., 2013; Kumari et al., 2008). 
While the striatum and thalamus are known to have the highest dopamine receptor 
concentrations in the brain, the frontal and temporal lobes also contains significant numbers of 
receptors on rigorous postmortem examination (Joyce et al., 1991). High-affinity dopamine 
receptor ligands developed for positron emission tomography (PET) make it possible to assess 
the fronto-striato-thalamic distribution of dopamine binding.  In healthy subjects significant 
extra-striatal binding has been demonstrated (Buchsbaum et al., 2006; Farde et al., 1997; Lehrer 
et al., 2005; Mukherjee et al., 2002). In unmedicated and never-medicated subjects with 
schizophrenia, abnormalities in extra-striatal dopaminergic neurotransmission have been 
reported in the prefrontal cortex (Lehrer et al., 2010a) and the medial dorsal nucleus of the 
thalamus (Buchsbaum et al., 2006; Kessler et al., 2009; Lehrer et al., 2005; Suhara et al., 2002; 
Talvik et al., 2003; Yasuno et al., 2004). The earliest report by  Suhara and colleagues (Suhara 
et al., 2002) showed lower binding potential in the thalamus in patients with schizophrenia 
compared with controls (in retrospect, a one-tailed test would have been  p=0.03; see their Table 
1). A single photon emission computed tomography (SPECT) study using epidepride (Glenthoj 
et al., 2006) failed to detect binding reduction in the thalamus in patients with schizophrenia, 
however this negative finding may be due to lower resolution in SPECT imaging. In our studies 
with higher-resolution PET the decreased binding in schizophrenia was most marked in the 
medial dorsal nucleus isolated by tracing on co-registered MRI (Lehrer et al., 2010b), whereas 
in healthy subjects, the medial dorsal nucleus showed relatively higher binding compared with 
other thalamic nuclei (Takahashi et al., 2006). 
 There is increasing evidence that patients with schizophrenia exhibit impairment on 
executive function tasks, such as the WCST and the California Verbal Learning Test (CVLT), 
which is precisely aligned to non-motor fronto-striatal-thalamic circuits. Performance deficits in 
WCST categories achieved and perseverative errors has been widely documented in  first-
episode psychosis (Addington et al., 2003; Bilder et al., 2000; Brickman et al., 2004; Fagerlund 
et al., 2006; Mohamed et al., 1999; Riley et al., 2000; Townsend et al., 2001), and meta-
analyses (Fatouros-Bergman et al., 2014; Fioravanti et al., 2005; Li, 2004). Functional MRI and 
PET frontal activation deficits have been found in schizophrenia (Berman et al., 1995; Patel et 
al., 2010; Riehemann et al., 2001) and an activation likelihood estimation meta-analysis on a 
series of fMRI studies using the WCST identified the frontal lobe, thalamus and striatum as 
important activation sites (Buchsbaum et al., 2005). The prevailing evidence from imaging 
studies suggests more widespread brain activations during WCST performance (Barcelo et al., 
1997; Nyhus and Barcelo, 2009). An EEG study of healthy individuals revealed increased 
activity during task performance across all frequency bands in the frontal and temporo-parieto-
occipital regions (except alpha), indicating that executive functioning skills underlying 
performance on the WCST may represent the operation of a more complex and widespread 
communication network (Gonzalez-Hernandez et al., 2002). Since dopamine  projections are 
widespread, dopamine deficits may have profound effects on higher-order cognition (Vyas et 
al., 2011).  
The CVLT, a measure of verbal learning and memory that relies on serial-order and 
semantic-cluster strategies, also involves frontal areas, as demonstrated in patients with focal 
lesions (Alexander et al., 2003; Baldo et al., 2002),  striatal  activity in PET studies of normal 
aging (Brickman et al., 2003), and reduced functional connectivity between the medial 
prefrontal, thalamus and striatum in fMRI studies of mild cognitive impairment (Liang et al., 
2011). Deficits in the CVLT have consistently been reported in early-onset (Brickman et al., in 
press; McClellan et al., 2004; Oie and Rund, 1999; Roofeh et al., 2006), first-episode (Bilder et 
al., 2000; Hill et al., 2001; Saykin et al., 1994), chronic / multiple-episode (Aleman et al., 1999; 
Heinrichs and Zakzanis, 1998) patients with schizophrenia, high risk studies (Hill et al., 2004; 
Paulsen et al., 1995), and a meta-analysis  (Szoke et al., 2008). 
Four  resting [F-18]fallypride PET studies in schizophrenia have reported low dopamine 
receptor binding potential in the medial dorsal nucleus of the thalamus (Buchsbaum et al., 2006; 
Kessler et al., 2009; Lehrer et al., 2010a; Yasuno et al., 2004), and in the prefrontal cortex in 
patients with schizophrenia (Lehrer et al., 2010a). A study using the high-affinity radioligand 
[11C]FLB 457 PET also showed low D2/D3 receptor binding in the right medial thalamus in 
drug-naïve patients with schizophrenia compared with controls (Talvik et al., 2003).  
Since excess dopaminergic activity has been hypothesized to be involved in the 
pathophysiology of schizophrenia, we might expect that poor WCST performance would be 
associated with a more active dopamine system. In subjects with schizophrenia, higher 
18
F-
FDOPA uptake has been associated with poor task performance on the WCST perseverative 
errors (Meyer-Lindenberg et al., 2002). Another study showed that more perseverative errors on 
the CANTAB Set shifting task were significantly associated with lower binding potential in 
patients with schizophrenia  (Fagerlund et al., 2013).  Ghahremani and colleagues reported 
better (shorter) stop-signal reaction time associated with higher fallypride binding potential in 
the striatum (Ghahremani et al., 2012).  
Animal models have demonstrated that the striatum plays an important role in decision-
making and performing goal-directed actions (Ito and Doya, 2009). Human choice behavior has 
been conceptualized as based on two decision systems, namely model-free and model-based, 
where the former system is influenced by making predictions based on previous experiences 
while the latter goal-directed system plans a set of actions based on future prospects. A recent 
study used a two-step decision choice task during fMRI combined with 18F-FDOPA PET in 
healthy participants, reported that higher levels of presynaptic dopamine in the ventral striatum 
was associated with greater model-based coding in the lateral prefrontal cortices  (Deserno et 
al., 2005).  Importantly, Ito et al. observed a significant negative correlation between the 
binding potential of dopamine D2 receptors and endogenous dopamine synthesis rate (Ito et al., 
2011) indicating that high dopa uptake and low binding potential are alternate assessments. 
The aim of the current study was to investigate the relationship between dopamine D2/D3 
receptor density, as indexed by [
18
F]fallypride, and executive function (as measured by the 
WCST), and episodic memory (as measured with CVLT), in a group of medication-naïve 
patients with schizophrenia and matched healthy volunteers. Because previous studies have 
shown low dopamine D2/D3 receptor binding potential in schizophrenia, we hypothesized that 1) 
there will be a positive association between high binding potential and performance in healthy 
volunteers 2) this association will be less pronounced in patients with schizophrenia due to 
dysfunctional dopamine deployment in the frontal cortex, 3) heterogeneous dopamine deficits in 
patients with schizophrenia will diminish regional brain fallypride binding potential vs. 
neuropsychological performance correlations, 4) there will be an association between binding 
potential and short-delay recall (model-free) in the ventral striatum in healthy volunteers, while a 
lower correlation will be found between binding potential and WCST categories achieved 
(model-based). 
  
2. Material and methods 
2.1. Subjects 
Twenty-five patients with schizophrenia (18 men; 7 women; age mean±SD: 31.6±12.2) 
were recruited from the greater Dayton, Ohio area, and assessed and consented as previously 
described (Buchsbaum et al., 2006; Lehrer et al., 2010a).  We clinically evaluated participants 
(Buchsbaum et al., 2006) (n=15) using the Comprehensive Assessment of Symptoms and 
History (Andreasen et al., 1992) and the Brief Psychiatric Rating Scale  (Overall, 1972, 1976). 
We clinically assessed later subjects (n=18) using the Positive and Negative Syndrome Scale  
(Kay et al., 1987), from which BPRS scores could be estimated for the purpose of combining all 
subjects.  Over the period of subject acquisition, other additional projects required the PANNS 
and the BPRS was inadvertantly not obtained on a few subjects. However the 
neuropsychological testing was maintained in a standard way throughout this period.  A board-
certified psychiatrist (D.S.L.) diagnosed all subjects using the Structured Clinical Interview for 
DSM-IV Axis I Disorders (First et al., 1996). A board-certified psychiatrist (author D.S.L.) 
diagnosed all subjects. He performed serial standard clinical psychiatric examinations on each 
and utilized available collateral information (family, treating clinicians, medical records). He 
confirmed each diagnosis using the Structured Clinical Interview for DSM-IV  Axis I Disorders 
(SCID-I). We followed the very few schizophreniform subjects (i.e., duration of illness less than 
six months at the time of study) in order to determine whether they eventually met criteria for 
schizophrenia; this diagnostic conversion occurred in all such cases. Twenty-one subjects were 
diagnosed with schizophrenia and four with schizoaffective disorder. Twenty patients were 
absolutely neuroleptic naïve, as confirmed by case notes and psychiatric interview, and five were 
previously medicated, although only three had a lifetime neuroleptic exposure of greater than 
two weeks. No subject had received neuroleptic within 30 days of study. This was verified in 
most cases with both clinical records and information obtained from relatives. Subject 
characteristics are summarized in Table 1. This sample size is slightly smaller than our previous 
report (Lehrer et al., 2010a) because in the process of reregistering the FDG-MRI-diffusion-
tensor-fallypride images a small number of subjects did not have the complete dataset.  
Nineteen normal control subjects (12 men; 7 women; mean age±SD: 29.2± 9.3) were 
recruited via newspaper and poster advertisement. Controls were age- and sex-matched to 
experimental subjects. The exclusion criteria for the control group included: (a) personal or family 
history of psychiatric illness, or intellectual disabilities; (b) personal or family history of hereditary 
neurological disorders, previous brain infections, Parkinson’s disease, significant medical 
disorders, or head injury resulting in a loss of consciousness for more than 1 h, and (c) DSM-IV 
criteria for psychoactive substance abuse in the preceding 6 months or the presence of co-morbid 
Axis I disorders. 
 
2.2. Cognitive assessment 
2.2.1.  Executive function  
A computerized version of the WCST:CV4  (Heaton, 2003; Milner, 1963)  was 
administered to all participants, who were instructed to match a response card to one of the four 
reference cards on the basis of three perceptual dimensions (shape, color, or number). Subjects 
were not informed of the correct sorting principle but were provided feedback on the response 
(‘Right’ or ‘Wrong’). The following performance indexes were of interest: (1) perseverative 
errors scored as  number of repetitive errors; (2) total errors: total number of perseverative and 
non-perseverative errors (presented as T-scores with positive values indicating better 
performance as fewer errors); (3) categories achieved: number of rules that have been correctly 
identified; and (4) extradimensional shift learning: loss of set or failure to maintain set. For 
correlation analyses, perseverative errors and shift learning signs were reversed so that all four 
scores had the direction of higher values with higher performance.  
 
2.2.2.  Verbal learning and memory 
Verbal learning and memory were assessed with the CVLT (Delis et al., 1987; Delis, 2000) 
in which a list of 16 words (List A) is read to the participant and they are instructed to recall as 
many items in any order on five consecutive trials. Each item can be classified into semantic 
categories (spices & herbs, tools, fruits, or clothing). Following trials 1-5, the participant is 
presented with an interference list of 16 new words (List B) over a single trial, immediately 
followed by a short-delay free recall trial. After a 20 minute delay, the participant is required to 
recall List A. Responses that do not match the target list during the recall trials are denoted 
intrusions. A 44-item yes-no recognition test for List A is assessed following the long delay 
recall trial. The outcome variables included total words recalled for trials 1-5, short-delay free 
recall, long-delay free recall (20 minute delay), learning slope, recognition hits, false alarms, 
response bias, and discriminability.  The CVLT also provides indexes to assess learning strategy, 
including semantic clustering (recalling the items consecutively in categories) and serial 
clustering (recalling items in the order in which they are presented). 
 
2.3. Imaging acquisition 
2.3.1. PET Scan 
The subjects refrained from alcohol and caffeine 4 hours before the PET scanning session. 
The PET scans were acquired using an ECAT EXACT HR+ scanner in 3D mode (Brix et al., 
1997) .The subjects were placed in the scanner in a supine position. The subjects’ head was fixed 
with a surgical tape as described earlier (Lehrer et al., 2010a). A 5-minute transmission scan was 
first acquired using a 
68
Ge/
68
Ga rod source to correct for the attenuation of photons. The dynamic 
acquisition of the PET dynamic data was initiated with a 30-second bolus injection of 
18
F-
fallypride. The radiopharmaceutical was produced according to previously reported methods 
(Mukherjee et al., 1995) at high specific activity (> 2800 Ci/mmole) with a dose of 0.7 mCi/10kg 
(range of 3.7 – 7.4 mCi). The initial subject cohort underwent two hours of dynamic PET imaging, 
while the later studied participants were scanned for three hours from start to finish, with a 20-
minute rest period mid-scan. The data were reconstructed using the ECAT v7.2 OSEM following 
corrections applied for attenuation, normalization, and scatter. Before  further data processing, the 
dynamic frames were spatially aligned using  AIR 3.08 software (Woods et al., 1992) was used to 
correct for head motion. The cerebellum was used to represent the reference region (devoid of 
specific ligand-receptor binding) for the data analysis. Multiple, circular regions of interest were 
placed over the outer lobules of the cerebellum, covering two 3.5-mm-thick transaxial planes to 
obtain cerebellar values. 
Co-registration to anatomical images was done by using early sum images. We registered the 
distribution volume ratio images to the MNI template (12-parameter affine registration model 
using FLIRT) and examined the individual standardized images. Thirty-seven achieved good 
registration, so a standard fallypride template was created from these individuals. Each fallypride 
image was then reregistered to the mean fallypride template. Next the transformation matrix for 
fallypride template to MNI standard brain was used to transform every fallypride subject to MNI 
space. We obtained binding potential uptake assessments using the analysis of functional 
neuroimages (AFNI) regions of interest.  
We examined the quality of co-registration by locating the edge of the caudate nucleus 
using an x-dimension voxel strip, and found the first derivatives of the binding potential (BP). 
The MRI were aligned within 1 mm in 82% of cases and within 2 mm in 16% of cases, 
indicating good co-registration. We further assessed the binding potential computation, co-
registration to MNI template and AFNI region of interest reliability on an independent series of 
fallypride scans of healthy volunteers and patients with schizophrenia collected at UCSD. Each 
of the three steps was carried out using similar or identical scripts. Scans at UCSD were 
collected as four frames and the process was applied to the odd and even frame totals 
independently, thus allowing assessment of all three steps each with attendant error. Since the 
counts were only approximately half as great, this might provide an underestimate of reliability. 
Product-moment correlations for reliability for the right and left nucleus accumbens were 0.99, 
0.99 and for right with left, 0.89 and 0.79.  The odd-frame left vs. even frame right correlations 
remained acceptable and are both anatomically independent (since they are more than 10 full-
width half-maximum apart) and statistically independent (entirely separate samples). Right vs. 
left pairings were sensitive to misalignment in structures near the edge, since a right/left shift can 
place part of the structure in CSF on one side but not the other. However, right-left pairs 
remained highly reliable even when they were not adjacent to brain edges. Other areas were 
similarly reliable, including cortical areas. 
 
2.3.2.  MR imaging 
 T1 weighted MRI images (1.5T) were acquired on a GE Signa NVi system (General 
Electric, Milwaukee) using the following parameters, TR=24 msec, TE=5 ms, flip angle=40°, 
slice thickness=1.2 mm, pixel matrix=256×256, field of view=23 cm, total slices=128.  
 
2.4. Data analysis      
Our strategy was to preselect AFNI anatomical areas associated with imaging 
abnormalities in schizophrenia and task performance. We prioritized the striatum, thalamus, and 
prefrontal cortex for analysis. Statistical analysis was performed using IBM Statistical Package 
for the Social Sciences (SPSS v.21).  Chi-square and Welch t-tests were applied to assess 
differences in demographic characteristics and cognitive performance in patients with 
schizophrenia in comparison with matched healthy volunteers. Multiple regression was carried 
out with R and package psych and missing data were imputed with R package e1071 which 
substituted the mean value for all subjects. All brain imaging values were present and all 
neuropsychological values were present for healthy controls but there were but there were 4 
Wisconsin Cart Sort Tests and  4 CVLT scores missing from the patient group (not both in the 
same patient in 2). The sample is slightly smaller than our previous report (Lehrer et al., 2010 
because we chose the individuals who had four images (fallypride, MRI, FDG, and fractional 
anisotropy) for planned multimodal analysis.  
Power was assessed by examining published dopamine BP correlations with task 
performance. The median explained variance with the CANTAB battery (Fagerlund et al., 2013) 
was 25.7%, corresponding to a correlation coefficient of 0.51. Our power to detect a significant 
correlation of 0.51 in 25 patients is 0.75 (Cohen, 1969, p 99).   Using CANTAB set-shifting as a 
proxy for the Wisconsin Card Sort Test, the z difference in correlations in patients with 
schizophrenia and healthy volunteers was approximately 1.00, which corresponds to a power of 
.91 for healthy/patient differences (Cohen, 1969, p 121)   
We calculated the distribution of correlation coefficients (scores by z-transformed ROI 
matrix) and compared the distributions with the Kolmogorov-Smirnov distribution and Welch t-
test (ks.test, in R).  The rectangular portion of the correlation matrix for neuropsychological 
scores vs. fallypride binding potential was compared between healthy and patient groups using a 
R language simulation since the regional binding potential and CVLT variables were correlated.  
We carried out 1000 random permutation simulations using the 44 subjects to form  1000 groups 
of 19 and 25 subjects, calculated the test statistic on each iteration,  and used the resulting table 
of the 1000 test statistics to test the significance of the healthy vs. patient correlation matrix 
differences. Thus the differences in correlation matrices between healthy and patient groups were 
confirmed statistically with a single permutation probability test.  
Maps of r correlations and Fisher Z tests to compare correlation maps are presented. A 
color bar from 0.05 to 0.001 is given to allow the reader to compare already published binding 
potential/task performance findings with ours as one-tailed confirmations or exploratory analysis 
depending on the viewer’s goal. These maps may be considered as 1) analogous to follow-up 
anova in a two factor repeated measures design where follow-up t-tests on individual cells are 
performed to localize the greatest effects, 2) confirmatory  of published binding potential vs 
cognitive performance correlations or 3) exploratory presentation of regional brain effects. The 
overall average Z differences were confirmed by permutation analysis as described above.  
 
2.4.1. Binding potential parametric image analysis 
The BP values reported here were calculated using a multilinear variation (Ichise et al., 
2002) of the Logan (Logan et al., 1996) distribution volume ratio (DVR). This model employs the 
use of a tissue reference region (cerebellum) to represent the kinetics of unbound radioligand in the 
tissue (Cunningham et al., 1991; Logan et al., 1996). More details of these methods can be found 
in our previous report (Buchsbaum et al., 2006). 
 
2.4.2. Regions of interest 
Selective AFNI regions of interest (ROIs) were calculated from each subject. We 
calculated product-moment correlation coefficients between each ROI and the brain areas.  For 
the neuropsychological measures we chose four WCST scores (categories achieved, 
perseverative errors, total correct, extradimensional set shifting) and nine scores for the CVLT.  
Based on earlier findings of fallypride binding reduction in the thalamus, frontal lobe and 
temporal lobe, on commonly reported regions showing brain imaging abnormalities, and the  
frontostriatal dopamine relationships shown in combined PET/diffusion tensor imaging studies 
(Tziortzi et al., 2014), we focused on 13 regions: the dorsal medial and lateral nuclei of the 
thalamus, the pulvinar, the medial and lateral geniculate, three superior/inferior levels of the 
caudate, the anterior (Brodmann area (BA) 32), and posterior cingulate (BA23), anterior 
cingulate cortex (BA24), and the medial and lateral globus pallidus. For an alternate view of 
dopaminergic activity, we chose the dorsolateral prefrontal region, and the medial and lateral 
temporal lobe, also regions widely confirmed as different in patients with schizophrenia 
(hippocampus, uncus,  parahippocampus, lingual gyrus, and Brodmann areas: 8, 9, 10, 44, 45, 
46, 47, 20, 21, 22) (Buckley, 2005; Davidson and Heinrichs, 2003; Ellison-Wright et al., 2008; 
Glahn et al., 2008). 
  
3. Results 
 
3.1. [F-18] Fallypride and WCST 
In the fronto-striatal-thalamic region set, there was no significant difference between 
healthy volunteers and patients on the four WCST scores and no difference was confirmed with 
the Hotelling T2 test (F=3.08, df=4, 39, p=0.23). The Hotelling T2 was at a trend level for the 13 
BP values (F=1.17, df=13, 30, p=0.054). The correlation coefficients between fallypride binding 
potential and WCST are shown in Figure 1. Healthy volunteers tended to show positive 
correlations indicating better performance with higher binding potential, in contrast to patients 
with schizophrenia who showed negative or very low correlations. We examined the distribution 
of the 52 correlations (4 WCST scores vs 13 binding potential regional values).  
The mean z-transformed correlation coefficients between the 4 WCST variables and the 13 
brain regions were 0.12 for healthy volunteers and -0.40 for patients with schizophrenia (see 
Table 2). The Kolmogorov-Smirnov test showed the distributions to be different (healthy/patient 
permutation, D=0.90, p<0.001) and the Welch t test (healthy/patient permutation, p<0.001).  The 
Jenkins-derived statistic was exactly 0.001. The difference between healthy volunteers and 
patients for the binding potential in the medial dorsal nucleus was significant (healthy volunteers 
BP=3.06, sd=0.31, patients BP=2.77, sd=0.33, p=0.0049, df=40.2, t=2.98). In the dorsolateral 
frontal-limbic-temporal region set (Figure 2), the BP values were significantly lower in patients 
(Hotelling T2 =45.5, df=14,29, p=0.049). The correlations between the 4 WCST scores and 14 
ROI (56) were more positive in healthy volunteers and this difference was significant by Welch 
t-test (t=6.05, df=109, permutation analysis, p<0.001) and Kolmogorov-Smirnov (D=0.46, 
permutation analysis, p=0.049). The distribution of correlations had a low kurtosis (-0.54 
p=0.034 simulation) value in healthy volunteers) and 0.34 in patients (kurtosis not significantly 
different from zero). The distribution of correlations in healthy volunteers had a skew of 0.14 but 
in patients it was -0.80 (p<0.001). Exploratory voxel-by-voxel maps or the correlation between 
the WCST perseverative errors and binding potential were calculated, and the Fisher z test for 
difference between correlation coefficients were applied (Figure 3). Better performance in the 
WCST perseverative errors was associated with higher binding potential in the frontal cortex and 
right temporal lobe and lower binding in caudate. The reverse pattern was observed in patients 
with schizophrenia. Patients with schizophrenia showed a negative correlation between binding 
potential and perseverative errors in the frontal cortex, and positive correlations in the striatum. 
 
3.2 D2/D3 receptor binding and the CVLT 
Patients with schizophrenia underperformed on the CVLT (Table 1) compared with healthy 
volunteers and this was also confirmed across all nine scores (Hotelling T2, F (9, 34)=2.57, 
p=0.022). Patients with schizophrenia tended to have lower binding potential for all 13 regions. 
This was significant on univariate testing for the medial dorsal nucleus of the thalamus (t=2.98, 
df=40.2, p=.004), the lateral dorsal nucleus (t=1.94, df=39.9, p=.05), and medial geniculate 
(t=2.26, df=36.1, p=.03) but not multivariate testing (Hotelling T2, F (13, 30)=1.17, p=0.35).  
The correlation coefficients between the fronto-striatal-thalamic fallypride binding 
potential set and CVLT are shown in Figure 4. Healthy volunteers showed positive correlations 
indicating better performance with higher binding potential, in contrast to patients who showed 
negative or very low correlations. 
We examined the distribution of the 117 correlations (9 CVLT scores vs. 13 binding 
potential regional values). The mean z-transformed correlation coefficients between the 9 CVLT 
variables and the 13 brain regions were 0.12 in healthy volunteers’ and -0.08 in patients. The 
regional distribution of 18F-Fallypride correlations was significantly different across groups. The 
Kolmogorov-Smirnoff D test confirmed a distribution difference in both groups, D=0.54, p= 
3.664e-15 permutational analysis (D=0.54, p=0.046) (see Figure 4).  The Welch t-test showed a 
significant difference between groups (t=9.03 df=230.3, p= 2.2e-16 and permutation test was 
p=0.025). We found the healthy sample (117 binding potential vs CVLT score correlations) to 
have significant negative skew (-0.7, permutation with random numbers, p<0.001) in comparison 
with the patient group (0.08) and permutation analysis with patients and healthy found this at the 
0.096 level. The healthy sample had greater positive kurtosis (0.65, permutation with random 
numbers, p=0.034) than patients with schizophrenia (-0.15) (permutation analysis with patients 
and healthy found this at the 0.098 level). The correlations between the dorsolateral frontal-
limbic-temporal lobe correlation coefficient data set (9 CVLT ×14 ROI=126 r) showed similar 
results with healthy volunteers having more positive correlations (mean: 0.16) than patients 
(mean: -0.07) (Kolmogorov-Smirnov D=0.69, permutation p=0.002, Welch t-test, t=15.66, 
df=248.2, p<0.001) (See Figure 5). Exploratory voxel-by-voxel maps or the correlation between 
the learning slope and binding potential were calculated, and the Fisher z test for difference 
between correlation coefficients was applied (Figure 6).  Successful CVLT performance, as 
defined by high learning over successive trials, was associated with high binding potential in the 
frontal lobes and in the cingulate gyrus in healthy volunteers. The reverse pattern was seen in 
patients with schizophrenia. This is the opposite of the expected effect since patients with 
schizophrenia are hypothesized to have high dopamine in the synapse but were observed to have 
low binding potential in these areas in contrast to healthy volunteers. Significant clusters of 
Fisher z-tests are presented in Table 3.  
3.3 Model-based analysis  
 We examined the similarity of our data to the ventral striatal F-DOPA uptake data of 
(Deserno et al., 2015). A Fisher’s Z comparison between the r correlation map of CVLT short-
delay vs. binding potential (analogue of model-free) and the r correlation map of WCST 
categories achieved(analogue of model-based)  showed a strong negative correlation in the 
ventral striatum but not the dorsal striatum. This was consistent with the positive correlation 
shown on the difference scores (Deserno et al., 2015). Patients with schizophrenia showed a 
positive correlation in the dorsal striatum, suggesting an entirely different dopaminergic 
mechanism involving the two hypothetical models (see Figure 7).  
4. Discussion 
 
To our knowledge, this study represents the first comprehensive investigation of the association 
between both striatal and extrastriatal D2/D3 receptor binding potential with executive function 
and verbal learning in medication-naïve (5 drug-free) patients with schizophrenia. The most 
important findings of this study are five-fold. Firstly, we found a positive correlation between 
binding potential and task performance on the WCST and CVLT in healthy volunteers. 
Secondly, we found lower or negative correlations between binding potential and task 
performance in patients with schizophrenia. Third, we found greater numbers of 
neuropsychological task performance vs binding potential outliers among correlation coefficients 
in healthy volunteers. Fourth, patients with schizophrenia had more negative and near zero 
correlations between performance and binding potential.  Fifth, in line with model-based systems 
theory, we found a significantly more positive correlation between binding potential and short 
delay performance (model-free) in the ventral striatum in healthy subjects than the correlation 
between binding potential and WCST categories (model-based) . 
 We found less dopaminergic function (high binding potential) associated with good 
performance in healthy controls. This was consistent with previous studies investigating D2/D3 
receptor binding during a stop-signal task (n=21) (Ghahremani et al., 2012), and the study of 
Vernaleken and colleagues who reported a correlation of 0.25 between caudate nucleus 18F-
FDOPA (net blood brain clearance) and WCST total errors (Vernaleken et al., 2007), close to our 
correlation of 0.27 in healthy volunteers and higher than our correlation in patients (r=-0.28). 
Similarly, Hsieh et al. found a negative correlation (r=-0.44) between striatal dopamine 
transporter (DAT) availability with perseverative errors in healthy subjects (good performance 
and low availability) (Hsieh et al., 2010) consistent with our finding of a positive correlation 
(good performance and high BP, r=0.27) in healthy volunteers, and a negative correlation in 
schizophrenia (r=-0.28) between dopamine binding and WCST. An 18F-F-DOPA uptake study 
reported a negative correlation between dopamine uptake (striatal Ki) and WCST perseveration 
error (good performance is low uptake) in schizophrenia (n=6) (Meyer-Lindenberg et al., 2002), 
a finding in the opposite direction. Consistent with previous drug-naïve or never-medicated 
schizophrenia studies (Andersen et al., 2013; Brickman et al., 2004; He et al., 2013; Hill et al., 
2004; Zhang et al., 2012), we found significant differences between schizophrenia and healthy 
volunteers on short and long-delay recall. The reported negative correlations between binding 
potential and performance on the CVLT and positive correlations in healthy comparisons are 
similar in pattern to those observed with the WCST.  
We examined the theoretical approach of Deserno and colleagues (Deserno et al., 2015) 
which evaluated the cognitive mapping of habitual and goal directed systems, termed “model-
free” and “model-based”.  Their description of the concepts of model-free and model bases 
appear analogous to CVLT short delay (models of learning based on past rewards) and WCST 
categories achieved (map possible actions to their potential outcomes). They found a positive 
correlation was between the ventral striatum F-DOPA and the difference in model-free and 
model based performance. Consistent with this, with binding potential, we found that the 
correlation between CVLT performance and binding potential in the ventral striatum but not 
dorsal striatum was significantly more negative than the correlation between WCST and binding 
potential (sign reversed since binding potential and F-DOPA uptake have related physiology but 
in opposite directions).   
 In a novel spatial attention activation 18F-Fallypride study using the Posner Flanker task 
(LaBerge and Buchsbaum, 1990; Posner, 1980), we showed an association between higher 
dopamine release and better performance in healthy volunteers (Christian et al., 2006). In the 
current study, we speculate that the better performance association with low binding potential 
might represent an adaptation of the disturbed dopamine circuitry connections. Our findings of 
negative correlation between extrastriatal binding potential and high performance only in 
patients with schizophrenia is consistent with the recent findings of Norbak-Emig et al. (Norbak-
Emig et al., 2016) who assessed epidepride binding before and after antipsychotic treatment and 
cognitive performance using the Rapid Visual Processing (signal detection A') test from the 
Cambridge Neuropsychological Test Automated Battery. They interpreted their data as 
suggesting “that blockade of frontal D2/D3 receptors by antipsychotics may worsen some 
cognitive domains possibly by compromising the optimal prefrontal network functioning, which 
is required for cognitive performance, motivation and learning” (Norbak-Emig et al., 2016). Our 
findings are in line with a SPECT study on first-episode drug-naïve patients with schizophrenia, 
reporting an association of D2/D3 receptor binding potential on cognitive measures of executive 
function (Stockings of Cambridge), attention (rapid visual information processing), and set-
shifting ability (intra-extra dimensional) using the CANTAB test battery (Fagerlund et al., 2013). 
The study also reported that the frontal D2/D3 availability was more highly represented during 
task performance in schizophrenia patients compared with healthy subjects. Taken together, 
these studies suggest that higher dopaminergic function may be associated with worse WCST 
performance in healthy individuals, diminishing flexibility, and that there may be the opposite 
association in schizophrenia. Indeed, perseveration in schizophrenia may be related to failure to 
generate or shift to a new plan, which may be consistent with both WCST perseverative scores 
and CVLT learning slope and semantic scores (Lanser et al., 2002). However, tasks with high 
attentional unvarying demands may show the benefits of greater dopaminergic function.  Our 
findings support the view that striatal dopamine might diminish in cognitive flexibility but assist 
attention and plays an important mechanistic role in mediating learned associations between cues 
and environmental interpretation.  
  We found relatively low correlation coefficients between performance and binding 
potential spread across many regions of interest. This is consistent with a widespread fronto-
temporal-occipital activation network during the WCST, a finding that resonates with 
connectivity studies suggesting a disorganization of brain anatomical networks in schizophrenia 
where there is a loss of hierarchical organization in which high clustering of high-degree nodes 
resulting in inefficient axonal wiring (Bassett et al., 2008). Computational studies demonstrate 
that broad dispersed modular networks are involved in dealing with high processing demands 
from the environment (Bullmore and Sporns, 2012). The WCST evaluates an individual’s ability 
to modify incorrect strategies in relation to environmental feedback and inhibit prepotent 
responses. Our findings suggest that schizophrenia may have dysfunctional modular organization 
networks (Yu et al., 2012) which set them apart from healthy subjects in meeting the higher-
order cognitive processing demands, despite relevant target sources, the frontal and temporal 
cortices, showing high correlates with WCST task performance. 
 Evidence suggests that schizophrenia may involve a dysfunction in the frontotemporal 
network that is responsive to executive demands in healthy subjects (Ragland et al., 1998). The 
findings indicate an inability to adapt to changes in ongoing cues and feedback during task 
performance. Evidence from personality studies have shown that impulsivity and inhibitory 
control predict (Fino et al., 2014) or are associated with (Leshem and Glicksohn, 2012) the 
WCST. Although deficits in WCST performance have been consistently reported (Fatouros-
Bergman et al., 2014), our earlier study of never-medicated patients (Brickman et al., 2004), and 
the current study sample showed no significant difference in scores but differences in functional 
neuroanatomy. This implies that the differences we found were not merely related to a difference 
in task performance but to differences in the relationship between regional binding potential and 
cognitive performance. We found a striking difference in striatal and extrastriatal binding 
potential between groups; good performance on the WCST was associated with high binding 
potential in healthy volunteers, whereas medication-naive patients with schizophrenia showed a 
negative correlation with lower binding potential associated with better performance. The pattern 
suggests widespread brain activation across fronto-temporal-occipital regions in schizophrenia 
during WCST task performance while healthy volunteers show enhanced binding potential in 
more ‘relevant’ anatomical regions based on executive task demands. Evidence suggests that 
performance on executive function tasks may be exacerbated by impulsivity traits which are 
associated with the failure to inhibit habitual responses and switch strategies necessary based on 
demands imposed by environmental feedback. A 18F-Fallypride PET study in healthy volunteers 
with amphetamine found that reduced D2/D3 receptor binding was associated with higher levels 
of impulsivity (Buckholtz et al., 2010). Executive function tasks demand greater reliance on 
higher-order conceptualization, strategy and the integration of feedback which requires a high 
level of cognitive flexibility to rapidly modify a response to environmental cues. Patients with 
schizophrenia show difficulties in rule switching (‘stuck in set tendency’) despite receiving 
negative feedback suggesting an extreme form of perseverative tendency (Crider, 1997; 
Schneider and Asarnow, 1987). The widespread correlation between fronto-temporal-and 
occipital region binding potential and WCST performance in medication-naive patients with 
schizophrenia may represent impulsivity trait features and a compensatory mechanism for 
meeting the demands of the task. The medication-naïve patient sample may also be bias in 
containing patients with better executive function than those remaining unhospitalised without 
medication. This matching in task performance between healthy volunteers and the patient group 
may be advantageous in holding performance level equal and allowing differences in functional 
anatomy unconfounded by performance to be evident. Ragland and coworkers (Ragland et al., 
1998) used selected poor performance volunteers on the WCST to test whether activation pattern 
differences between volunteers and patients with schizophrenia were only due to performance 
deficits rather than changes in functional anatomy. 
  Limitations of this study include the sample size, but the difficulties of obtaining never-
medicated patients with schizophrenia cannot be underestimated. The sample size was sufficient 
to demonstrate reduced binding potential for the thalamus and other regions and to demonstrate 
reduced performance in the CVLT. The patient selection may be biased by refusing medication 
and remaining un-hospitalized for much or all of their illness and in a few cases refusing 
medication after a single dose. However the fact that they did not have their receptor numbers 
and sensitivity affected by chronic medication is a major advantage of this sample. A second 
limitation is the separation between scanner binding potential while resting correlated with pre-
scan neuropsychological evaluation. Any task performance correlation must then reflect trait 
features of dopaminergic levels of activation and trait features of cognitive performance. The 
alteration of dopamine function in schizophrenia is hypothesized to be genetic and stable and the 
test-retest reliability of the WCST over time has been documented (Seidman et al., 1991): these 
stabilities support our approach. A third limitation is the possibility that patients with 
schizophrenia had more head movement during the scan acquisition and therefore had less 
reliable scans. Three studies report that head motion is no greater in patients with schizophrenia 
than healthy volunteers (Buchsbaum et al., 2007; Mayer et al., 2007; Yoo et al., 2005). Power 
and coworkers report that head motion produces higher intercorrelations of structures close 
together and lower correlations of structures that are far apart as expected from the effect of the 
blurring of adjacent voxels (Power et al., 2012) .  However, examination of our binding potential 
data indicates that adjacent regions (e.g. BA 20 and 21) showed Fisher z scores close to zero 
when healthy and patients were compared, which is inconsistent with the head-motion 
contribution to group differences in this data set.  
 Ballard and coworkers (Ballard et al., 2015) reported the WCST proportion of non-
perseverative errors to be positively correlation (although non-significant) with striatal D2/D3 
receptor availability in methamphetamine users, while a negative correlation was found for non-
user controls. In contrast, a similar analysis on the number of non-perseverative errors in our 
sample showed a positive correlation with striatal D2/D3 binding potential in healthy volunteers, 
and a negative correlation (all non-significant) in schizophrenia. The inconsistency in findings 
may reflect differences in dopamine physiology between unmedicated methamphetamine users 
and patients with schizophrenia, or related to the significant weakness between the different 
correlations. 
 Healthy volunteers showed increased skewness and negative kurtosis in the r 
distributions. The activation imaging of the WCST shows small areas of activation, and large 
areas of lack of significant activation. Thus one would expect some few regions with high 
correlations with performance and more regions with low or zero correlations, a skewed 
distribution. If patients with schizophrenia had poorer activation or activation more variable in 
brain region between subjects then diminished skewness would be expected, consistent with our 
observation. However we also observed significant negative kurtosis, an indicator of a 
distribution that is flatter. This combination of skewness and negative kurtosis suggests that 
healthy individuals have not only more high value correlations but also more distributed low 
value correlations: a pattern of several areas of high correlation combined with diffuse 
participation of dopamine binding across wide brain areas. Patients with schizophrenia were not 
significantly skewed or kurtotic, suggesting heterogeneous dopamine deployment and/or weak, 
variable performance.  
The link between neuroleptic medication use and its influence on executive function task 
performance has been controversial. Some studies have reported significant improvements in the 
WCST following olanzapine medication (Borkowska et al., 2002; Harvey et al., 2003; Rossi et 
al., 1997), both olanzapine and risperidone (Bilder et al., 2002), or amphetamine challenge 
(Slifstein et al., 2010), while others have not (Green et al., 2002; Purdon et al., 2000), including a 
follow-up study involving WCST assessment at four time points following risperidone and 
conventional neuroleptic medication use in schizophrenia (Remillard et al., 2005).  We suggested 
above that tasks requiring greater flexibility such as the WCST might benefit from low 
dopaminergic activity while tasks requiring low flexibility but continuous attention might benefit 
from higher dopaminergic activity. A beneficial effect of haloperidol on WCST and a 
detrimental effect of haloperidol on reaction time were noted in a four week random assignment 
medication trial (Gallhofer et al., 2007). 
Our findings in this study reinforce the concept of distributed influence of dopamine on 
performance involving both striatal and extrastriatal regions. These influences are trait-like in 
nature extending across cognitive tasks in healthy subjects. Patients with schizophrenia show 
relationships between performance and binding potential that are anomalous and likely 
heterogeneous, leaving a disturbed distribution of regional binding potential versus performance 
correlations. Our findings are also consistent with the widely interconnected network patterns 
observed in fMRI connectivity studies rather than with a restricted network of several small, 
localized, and specialized neural loci.   
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Table 1.  Demographic characteristics and WCST performance in patients with schizophrenia and healthy volunteers 
 
Parameter Schizophrenia (n=25) Healthy volunteers (n=19) 
 
Statistic 
Age, years 31.6 (12.2) 29.2 (9.2) t=-.73 (42), p=.46 
 
Sex, M/F 
 
18/7 
 
12/7 
 
Fisher’s Exact test =.74 
 
Ethnicity, no. white/African American, African-
Jamaican/African-Caribbean/Mixed 
 
16/0/1/1/1 
 
 
22/ 3/ 0/ 0/ 0 
 
χ2=6.24, p=.18 
Handedness, no. right/left-handed 23/2 16/3 Fisher’s Exact test =.3 
 
WCST 
    Categories achieved 
 
 
5.36 (1.34) 
 
 
5.72 (0.95) 
 
 
t=.21, df=34, p=.52 
    Perseverative errors 
    Shift learning 
    Total errors (T score) 
 
14.78 (10) 
.75 (.06) 
50.8 (11.83) 
11.72 (6.76) 
.41 (.71)  
50.38 (10.98) 
t=-1.24. df=36, p=0.22 
t=-1.1, df=35, p.27 
t=-.11, df=36, p=.91 
CVLT    
    Trials 1-5 43.4 (9.34) 54.68 (9.2) t=3.79, df=37, p=.001 
    Short-delayed recall 9.33 (3.75) 11.52 (2.96) t=2.03, df=38, p=.049 
    Long-delayed recall 9.57 (3.75) 11.89 (3.36) t=2.11, df=36, p=.042 
    Learning slope 1.39 (.61) 1.43 (.56) t=.21, df=37, p=.828 
    Semantic cluster .44 (1.09) 1.9 (2.15) t=2.69, df=37, p=.01 
    Recognition 'hits' 13.65 (1.59) 14.73 (1.28) t=2.33, df=37, p=.026 
    Discrimination 2.65 (.81) 3.27 (.72) t=2.56, df=37, p=.016 
    False positives 2.8 (3.04) 1.26 (1.88) t=.04, df=37, p=.06 
    Response bias .14 (.28) .12 (.34) t=.87, df=30, p=.86 
 
Duration of illness 
 
204 (237.3) 
 
– 
 
 
– 
 
Medication status, n 20 medication-naïve; 5 previous 
medication use 
– 
 
– 
 
 
 Table 2. Wisconsin Card Sort score correlations with fallypride binding potential in healthy volunteers and patients with schizophrenia 
 
Healthy volunteers  
                                     Perseverative   Total        Categories    fail-set 
                                     Errors          Correct      achieved  
medial dorsal thalamus               -0.1267         -0.043         0.174       -0.397 
lateral dorsal thalamus              -0.3022          0.047         0.387       -0.478* 
pulvinar                             -0.2470          0.028         0.213       -0.316 
medial geniculate thalamus            0.1170         -0.107        -0.093       -0.261 
lateral  geniculate thalamus         -0.0617         -0.035         0.136       -0.354 
ventral caudate                       0.0130          0.171        -0.169       -0.087 
middle caudate                       -0.1067          0.226        -0.054       -0.147 
dorsal caudate                       -0.2761          0.219         0.170       -0.253 
Brodmann area 23                      0.0349         -0.021        -0.028       -0.175 
Brodmann area 24                     -0.0249         -0.020         0.102       -0.215 
Brodmann area 32                      0.0084         -0.093        -0.081       -0.114 
medial globus pallidus               -0.2613          0.080         0.114       -0.123 
lateral globus pallidus              -0.1656          0.133        -0.056       -0.138 
 
Patients with schizophrenia  
 
medial dorsal thalamus                0.363         -0.328         -0.60*        0.470* 
lateral dorsal thalamus               0.351         -0.438*        -0.63*        0.512* 
pulvinar                              0.424*        -0.445*        -0.66*        0.553* 
medial geniculate thalamus            0.253         -0.401*        -0.28         0.099 
lateral geniculate thalamus           0.437*        -0.431*        -0.47         0.327 
ventral caudate                      -0.047          0.079         -0.16        -0.190 
middle caudate                        0.244         -0.282         -0.54*        0.146 
dorsal caudate                        0.573*        -0.637*        -0.74*        0.356 
Brodmann area 23                      0.252         -0.429*        -0.46*        0.167 
Brodmann area 24                      0.196         -0.332         -0.46*        0.263 
Brodmann area 32                      0.215         -0.257         -0.46*        0.320 
medial globus pallidus                0.447*        -0.403*        -0.66*        0.300 
lateral globus pallidus               0.300         -0.277         -0.57*        0.147 
 
Fisher z comparison of correlations 
 
medial dorsal thalamus               -1.55         0.91            2.66         -2.83* 
latera dorsal thalamus               -2.07*        1.57            3.50**       -3.31** 
pulvinar                             -2.15*        1.54            3.07*        -2.89* 
medial geniculate thalamus           -0.43         0.97            0.51         -1.12 
lateral geniculate thalamus          -1.62         1.30            1.97         -2.16* 
ventral caudate                       0.18         0.28           -0.03          0.32 
middle caudate                       -1.08         1.58            1.68         -0.90 
dorsal caudate                       -2.85*        2.97*           3.45**       -1.92 
Brodmann area 23                     -0.68         1.33            1.44         -1.05 
Brodmann area 24                     -0.68         0.99            1.84         -1.49 
Brodmann area 32                     -0.64         0.51            1.28         -1.36 
medial globus pallidus               -2.28*        1.54            2.78*        -1.32 
lateral globus pallidus              -1.45         1.27            1.81         -0.87 
 
For Fisher z, *=p<0.05, ** Bonferroni corrected p<0.05 based on assumption of independence and 0.05/52.  
  
Table 3. CVLT learning slope correlation with fallypride binding potential compared in healthy volunteers and patients 
 
Cluster 
number 
Talairach 
coordinates 
Volume 
mm
3
 
Maximum  
z 
p value Regions 
x y z  
1 41 -53 -19 2115 3.87 0.000055 Right Fusiform gyrus, BA 37 
2 45 45 -17 1017 3.18 0.00074 Right Middle, inferior frontal gyrus, BA 11, 47 
3 29 -43 7 991 2.90 0.0019 Right Parahippocampal gryus, hippocampus, caudate tail 
 
4 -31 -75 -7 904 -1.69 0.049 Left Middle frontal gyrus, BA 9,46 
5 -39 45 -17 773 2.85 0.0022 Left middle frontal gyrus, BA 46, 11 
6 25 -77 -5 569 -1.69 0.049 Right Occipital lobe, lingual gyrus, BA 18, 19 
 
7 -39 -9 -15 536 -1.69 0.049 Left Occipital lobe BA 18, 19, parahippcampal gyrus 
 
8 -35 23 -31 417 2.68 0.0038 Left parahippocampal gyrus, fusiform, BA 36, 20 
 
9 61 -13 -11 359 2.87 0.0020 Right temporal lobe 
10 11 41 17 265 2.43 0.0075 Right medial frontal gyrus, anterior cingulate, BA 9, 32, 
10 
 
 
The CVLT learning slope is the rate of increase in the number of words remembered out of 16 across the five trials. Maps of the 
correlation coefficients between the slope values and binding potential were calculated for healthy volunteers and patients and then 
compared with the Fisher z test.  
Positive z value indicates more positive correlation between learning slope and binding potential in healthy volunteers than 
patients with schizophrenia. Negative z value indicates more positive correlation between learning slope and binding potential in 
patients with schizophrenia than healthy volunteers.  
Figure 1. Correlations between WCST and fallypride binding heat maps and Fisher z comparison in patients 
with schizophrenia in comparison with healthy volunteers. 
 
 
 
Heat maps show the inter-correlation of binding potential regions and WCST scores in both groups. WCST_Psv 
(WCST Perseveration), WCST_T (T score for total errors, higher value is good), WCST_Cat (WCST 
Categories achieved, higher value is good) and WCST_SL (WCST shift learning, higher value is good). The 
region abbreviations are defined in Table 2. Scale bar shows correlation coefficient value for the left and right 
panel of the upper row and the z value for the Fisher test of correlation coefficient differences for the left panel 
in the lower row. The right side of the lower row shows histograms of the subset of 52 correlations between 
fallypride binding ROI and WCST scale scores (4 WCST scores × 13 binding potential values). The healthy 
volunteers show positive correlations (yellow) indicating that high binding potential (i.e. less dopamine in 
synapse) is associated with better performance. However patients show the reverse (blue) indicating low 
binding potential (i.e. more dopamine in synapse) is associated with better performance. This distribution 
difference is statistically confirmed (see text) and can also be seen in the histograms of the 104 correlation 
coefficients for fallypride binding vs CVLT scores. Healthy volunteers (green bars) show a slightly skewed 
positive value distribution while patient with schizophrenia (red bars) have a larger negative correlation set. 
Note that signs of WCST-Psv and WCST-fail set have been reversed in the upper right so that all four variables 
have higher values for better performance. 
 
 
Figure 2. Fronto-temporal correlations between WCST and fallypride binding heat maps and Fisher z 
comparison in patients with schizophrenia in comparison with healthy volunteers.  
 
Heat maps show the inter-correlation of binding potential regions and WCST scores in both 
groups. The right side of the lower row shows histograms of the subset of 56 correlations 
between fallypride binding ROI and WCST scale scores (4 WCST scores × 14 binding 
potential values). The healthy volunteers showed mostly positive correlations (red and 
yellow) indicating that high binding potential is associated with better performance, whereas 
patients with schizophrenia showed  negative correlations (blue).  The histograms show some 
overlapping correlation coefficients for fallypride binding and WCST. Abbreviations are 
hippocampus (hippo), parahippocampal gyrus (parahippo), and lingual gyrus (lingual). 
Brodmann are numbered. 
Figure 3. Correlations between WCST perseveration and fallypride binding potential 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Left: Healthy volunteers’ product moment correlation between WCST and fallypride binding potential. Middle: Patients with 
schizophrenia Right: Fisher z-test for difference in correlations with red-yellow indicating healthy volunteers correlations 
more positive than patients. Note that healthy volunteers with better performance have higher binding in frontal cortex and 
right temporal lobe and lower binding in caudate. In contrast patients tended to have negative correlations between binding 
potential and perseveration in the frontal cortex (high binding potential associated with low error) and positive correlations in 
the striatum (high binding potential associated with high error).
Figure 4. CVLT vs Fallypride Binding Potential Heat maps and Fisher z comparison in patients with 
schizophrenia in comparison with healthy volunteers. 
 
 
 
The heat maps show the inter-correlation of binding potential regions and CVLT scores in both groups. Scale 
bar shows correlation coefficient value for the left and right panels of the upper row and the z value for the 
Fisher test of correlation coefficient differences for the left panel in the lower row. The right panel in the lower 
row shows histograms of the subset of 117 correlations between fallypride binding ROI and CVLT scale scores.  
The difference is marked in the subset region of fallypride in the thalamus with CVLT total score (see upper left 
of heat maps for healthy and patients). The healthy volunteers show positive correlations (red) indicating that 
high binding potential (i.e. less dopamine in synapse) is associated with better performance. However patients 
show the reverse (blue) indicating low binding potential (i.e. more dopamine in synapse) is associated with 
better performance. This distribution difference is statistically confirmed (see text) and can also be seen in 
Fisher z test in the left lower row.  The histograms of the 117 correlation coefficients for 13 fallypride binding 
regions  vs. 9 CVLT (13 ×9=117) scores is shown in the lower right. Healthy volunteers (green bars) show a 
negative skewed value distribution while patient with schizophrenia (red bars) have a larger negative correlation 
sets. The abbreviations for regions are shown in Table 2.  
 
Figure5. CVLT vs Fronto-temporal fallypride Binding Potential Heat maps and Fisher z 
comparison in patients with schizophrenia in comparison with healthy volunteers.  
 
 
 
 
 The heat maps show the inter-correlation of binding potential regions and CVLT scores in both 
groups. Scale bar shows correlation coefficient value for the left and right panels of the upper 
row and the z value for the Fisher test of correlation coefficient differences for the left panel in 
the lower row. The right panel in the lower row shows histograms of the subset of 117 
correlations between fallypride binding ROI and CVLT scale scores.  The difference is marked 
in the subset region of fallypride in the temporal cortices (BA21) with CVLT total score (see 
upper left of heat maps for healthy and patients). The healthy volunteers show positive 
correlations (red) indicating that high binding potential (i.e. less dopamine in synapse) is 
associated with better performance. However patients show the reverse (blue) indicating low 
binding potential (i.e. more dopamine in synapse) is associated with better performance. This 
distribution difference is statistically confirmed (see text) and can also be seen in Fisher z test in 
the left lower row.  Healthy volunteers (green bars) show a positive skewed value distribution 
while patient with schizophrenia have a larger negative correlation sets. . Abbreviations are 
hippocampus (hippo), parahippocampal gyrus (parahippo), and lingual gyrus (lingual). 
Brodmann are numbered. 
 
Figure 6. Correlations between CVLT learning slope and fallypride binding potential 
 
 
 
Left: Healthy volunteers’ product moment correlation between learning slope and fallypride binding potential. Middle: Patients with 
schizophrenia Right: Fisher z-test for difference in correlations with red-yellow indicating healthy volunteers’ correlations more positive than 
patients. Note that healthy volunteers with better performance have higher binding in frontal cortex and right temporal lobe and lower binding in 
parahippocampal areas. In contrast patients tended to have negative correlations between binding potential and learning slope. Color bar shows 
Fisher Z test at p<0.05 to p<0.001, 1 tailed.  
 
Figure 7. Correlation differences in [F-18]fallypride binding potential between WCST 
categories achieved and CVLT short delay recall in healthy subjects and patients with 
schizophrenia.  
  
 
 
 
 
A: Fisher z-test for difference in correlations between CVLT short delay vs BP and WCST 
categories achieved vs. BP with blue indicating a more positive correlation with WCST. This 
indicates that higher binding potential is associated with better performance on short-delay 
recall in healthy subjects in the ventral striatum and the correlation with the WCST is lower. 
Thus, the r correlation map of CVLT short-delay vs. binding potential (analogue of model-
free) and the r correlation map of WCST categories achieved (analogue of model-based) 
showed a strong negative correlation in the ventral striatum (cerise arrow) but not the dorsal 
striatum.  
B: Patients with schizophrenia showed a different pattern with correlations missing the ventral 
striatum but extending into the globus pallidus ventrally and the caudate nucleus dorsally 
 
C: Binding potential Fisher Z correlation difference in the ventral striatum in healthy subjects 
enlarged to show anatomical detail with slice between 31 and 33, upper left of panels A and B.  
 
D: Binding potential Fisher Z correlation difference in the ventral thalamus region of patients 
with schizophrenia 
 
